| Name | Allergy Therapeutics |
|---|---|
| Epic | AGY |
| Isin | GB00B02LCQ05 |
| Index | MID300 |
| Industry | Pharmaceuticals & Biotechnology |
| Latest share price | 5.25p | Net gearing | n/a |
|---|---|---|---|
| Market capitalisation | £250.24 | Debt ratio | n/a |
| Shares in issue | 4,766.44 | Debt-to-equity ratio | n/a |
| P/E ratio | n/a | Assets / equity ratio | n/a |
| Total dividends per share | n/a | Price to book value | n/a |
| Dividend yield | n/a | ROCE | -130.39 |
| Dividend cover | n/a | EPS growth | n/a |
| Earning per share | -7.61 | 52-week high / low | 1.73p / 6.00p |
| Type | Ex-date | Pay-date | Net-dividend |
|---|---|---|---|
| No dividends declared | |||
| Company name | Allergy Therapeutics |
|---|---|
| Address | Dominion Way, Worthing, West Sussex, United Kingdom, BN14 8SA |
| Telephone | +44 (0) 1903 844 700 |
| Website | http://www.allergytherapeutics.com/ |
| Director | Position |
|---|---|
| Mr Manuel Llobet | CEO |
| Mr Cheryl MacDiarmid | Non-Executive Director |
| Mr Zheqing Shen | Non-Executive Director |
| Mr Anthony Parker | Non-Executive Director |
| Mr Peter Jensen | Non-Executive Chairman |
| Mr Shaun Furlong | Chief Finance Officer |
| Dr Tunde Otulana | Independent Non-Executive Director |
| Assets £ (m) | 2023 | 2022 | 2021 |
|---|---|---|---|
| Reporting date | 30/06/23 | 30/06/22 | 30/06/21 |
| Intangible asssets and goodwill | 4.4 | 5.04 | 4.75 |
| Investments and other non-current assets | 5.81 | 5.96 | 5.76 |
| Total non-current assets | 34.19 | 31.19 | 30.23 |
| Inventory / work in progress | 11.59 | 11.41 | 10.84 |
| Trade and other receivables | 7.77 | 10.47 | 6.22 |
| Cash and equivalents | 14.85 | 20.52 | 40.27 |
| Other current assets and asset held for resale | n/a | n/a | 0.52 |
| Total of all assets | 68.4 | 73.58 | 88.09 |
| Liabilities £ (m) | 2023 | 2022 | 2021 |
|---|---|---|---|
| Short term liabilities | 19.06 | 18.05 | 18.23 |
| Long term liabilities | 54.13 | 17.13 | 21.32 |
| Other liabilites / pension etc | n/a | n/a | n/a |
| Total of all liabilities | 73.18 | 35.18 | 39.55 |
| Net assets £ (m) | 2023 | 2022 | 2021 |
|---|---|---|---|
| Net assets | -4.78 | 38.4 | 48.53 |
| Equity £ (m) | 2023 | 2022 | 2021 |
|---|---|---|---|
| Share capital | 0.69 | 0.65 | 0.65 |
| Minority interests | n/a | n/a | n/a |
| Retained earnings | -168.72 | -117.91 | -107.4 |
| Share premium account | 119.03 | 112.58 | 112.58 |
| Total equity | -4.78 | 38.4 | 48.53 |
| Income £ (m) | 2023 | 2022 | 2021 |
|---|---|---|---|
| Turnover | n/a | n/a | n/a |
| Operating profit | -36.13 | -12.24 | 4.03 |
| Pre-tax profit | -49.83 | -12.66 | 3.66 |